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Bullets points: 
 Immunocompromised individuals such as organ transplant recipients (OTR) are at 
elevated risk of developing keratinocyte carcinomas (KC), particularly cutaneous 
squamous cell carcinoma (cSCC) and progression from normal skin through actinic 
keratoses, cSCC and metastasis appears to be accelerated compared to 
immunocompetent individuals. 
 Interactions between ultraviolet radiation, dysregulated immune surveillance, direct 
pro- and anti-carcinogenic effects of drugs, oncogenic viruses (in particular beta genus 
human papillomaviruses) and host genetic susceptibility factor are likely to contribute to 
the pathogenesis of cSCC in OTR. 
 Additional research on critical cancer drivers and the nature of the interplay between 
these potentially synergistic cofactors may lead to development of clinically useful 
prognostic and predictive biomarkers and more targeted therapeutic and preventative 
strategies also relevant to other immunocompromised patient populations and the 
general population. 
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Abstract  
The pathogenesis of keratinocyte carcinoma following organ transplantation is 
multifactorial, and recent evidence suggests a complex and often synergistic interplay 
between the carcinogenic effects of ultraviolet radiation, compromised immune 
surveillance, direct pro- and anti-carcinogenic effects of drugs, oncogenic viruses (in 
particular beta genus human papillomaviruses) and host genetic susceptibility factors. We 
present an overview of those factors for which there is currently the most convincing 
evidence and highlight important gaps in our knowledge. In particular, a clear understanding 
of the interdependence and relative contributions of these cofactors is currently lacking, yet 
has important implications for rational development of clinically relevant biomarkers and 
targeted strategies for treatment and prevention of post-transplant keratinocyte cancers. 
  
 
 
Introduction  
The immune system plays a critical role in skin cancer development, progression and 
response to treatment. Keratinocyte cancers (KC) in immunocompromised individuals 
represent a growing challenge in terms of their frequency, multiplicity and often accelerated 
progression. Solid‐organ transplant recipients (OTR) are one of the best studied 
immunocompromised populations and, as summarised in the accompanying review,1 the 
overall risk for cutaneous squamous cell carcinoma (cSCC) is more than 100-fold greater 
than the general population.2-4 As in immunocompetent individuals (ICP), ultraviolet 
radiation (UVR) plays a major causal role, but other factors  - altered immune surveillance, 
drugs, oncogenic viruses, tumour genetic/epigenetic alterations and host genetic 
susceptibility factors - may hold the key to explaining observed differences in epidemiology, 
clinical features and biological behaviour of OTR cSCC and may also contribute to the 
pathogenesis of cSCC in other immunodeficiencies such as HIV, chronic lymphocytic 
leukaemia, and immune-mediated inflammatory disorders.5 In this review we summarise 
key aspects of current evidence providing insight into the influence of these factors on cSCC 
development and progression. We indicate where we consider further research is required 
to better understand their relative pathogenicity and interdependence and on how we 
might use this knowledge to develop future strategies for modifying their clinical impact. 
 
Ultraviolet radiation  
UVR is the principle environmental carcinogen responsible for OTR cSCC and Madeleine et al 
summarise the epidemiological and clinical evidence supporting this association1: more 
prevalent in regions of high ambient solar radiation, the majority occur on photo-exposed 
body sites,  are more common in fair skin phototypes and those with a history of chronic UV 
exposure and/or episodes of childhood sunburn.3,5,6 Photocarcinogenesis is the result of 
both immunomodulatory and mutagenic effects of UVR and, at the molecular level, 
targeted and whole exome sequencing studies in OTR cSCC confirm a high prevalence of UV‐
associated mutations.7  As discussed below, certain drugs commonly used in transplantation 
- including azathioprine, cyclosporine, and voriconazole - may interact directly or indirectly 
with UVR to enhance its carcinogenic effects; human papillomavirus (HPV) may also 
cooperate with UVR to promote squamous carcinogenesis5. Improved understanding of how 
 
 
these factors synergise with the effects of UV exposure at a cellular level may ultimately 
improve future attempts to limit or modify post-transplant UV carcinogenicity5.  
 
Immune surveillance and drugs used in transplantation  
Reduced immune surveillance due to induction and maintenance immunosuppressive drug 
regimens is a major contributory factor in the increased skin cancer risk of OTRs9. However, 
establishing the differential risk conferred by individual drugs at an epidemiological level is 
challenging and some published data are conflicting.1,5,9 Both duration and dose intensity 
may be as important as the specific drugs used: risk increases with time post-transplant;1,3 
low-dose cyclosporine is associated with a fewer cSCC;10 CD4 counts are significantly lower 
in OTR with cSCC;11 and less intensive immunosuppression in liver compared with other 
OTRs may account for their lower cSCC rates.12 Such observations underpin the practice of 
dose reduction in OTR with KC, although the optimal timing, method and efficacy of this 
approach compared to switching immunosuppressive regimens has not been systematically 
evaluated.13 
 
Direct pro-carcinogenic properties have also been identified for specific immunosuppressive 
drugs, the mechanisms often involving enhanced UV carcinogenicity5,9. Azathioprine, an 
inhibitor of de novo purine synthesis, is associated with selective ultraviolet A (UVA) 
photosensitivity and mutagenic effects in the skin14-17. The azathioprine metabolite 6-
thioguanine (6-TG) replaces a small proportion of DNA guanine and becomes a strong UVA 
chromophore, interacting with UVA to generate reactive oxygen species which cause 
widespread DNA damage and protein oxidation; the latter damages the DNA repair 
proteome, increasing UVB mutagenicity.14,15 Azathioprine photosensitivity is clinically 
measurable16, may be associated with a specific genetic signature17 and can be reduced by 
switching from azathioprine to mycophenolate mofetil (MMF), although azathioprine 
metabolites may persist in the skin for several years after withdrawal.18 MMF belongs to the 
same broad class of antimetabolite as azathioprine, replacing it from the mid-1990s9. There 
is a signal from cohort data that it may induce fewer cSCC,19,20 although this may be 
confounded by era effects with, for example, patients receiving MMF also benefitting from 
greater screening and photoprotection advice compared with earlier cohorts on 
azathioprine. Thus, there is no clear evidence that conversion to MMF reduces tumour 
 
 
accrual. Calcineurin inhibitors (CNIs, e.g. cyclosporine, tacrolimus) also demonstrate 
synergistic interactions with UVB and UVA5,9 through diverse mechanisms including reduced 
nucleotide excision repair and apoptotic response, enhanced UVB‐induced inflammation 
and angiogenesis, UVA potentiation of oncogenic ATF3 induction as well as UV independent 
mechanisms including increased TGFbeta production / signalling and suppression of p53‐
dependent senescence by ATF3 induction. 5,21,22  
 
In contrast, anti-carcinogenic effects have been observed with mammalian target of 
rapamycin (mTOR) inhibitors, including sirolimus (rapamycin) which was introduced in 
1999.23 Several prospective randomised trials have shown a decreased incidence of cSCC in 
OTRs switched from CNIs to sirolimus, an effect which is more significant if this conversion is 
early, specifically after the first cSCC.24,25. The anti-carcinogenic effects of mTOR inhibitors 
may be related to properties including inhibition of tumour vascularisation by suppression 
of VEGF; promotion of autophagy‐mediated DNA repair; alterations in AKT and EGFR 
signalling; and promotion of memory T‐cell function5,9,26,27,28. The greater effect on cSCC 
compared with BCC may relate to differential phospho-mTOR expression.29 There have been 
recent concerns that benefits in skin cancer reduction are outweighed by adverse effects: 
analysis of 5876 OTRs from 21 randomised trials confirmed a 56% reduction in KC in OTRs 
receiving sirolimus, but this was accompanied by an unexplained increased risk of death.23 
However, this may reflect the generally higher doses of sirolimus used in some of the early 
studies included in this analysis with adverse consequences that are now avoided by lower 
dosing.  Reassuringly, a recent retrospective study showed a reduction in skin cancer but no 
difference in graft rejection or survival between patients switched to sirolimus versus those 
not switched after post-transplant cancer.30  
 
The risk of many newer immunosuppressive drugs remains uncertain and their evaluation 
complicated by multiple confounders, particularly duration of use. For example, belatacept, 
a selective T-cell co-stimulation blocker, has been used as an alternative to cyclosporine 
since 2011. It seems to be associated with similar skin cancer incidence in recent trials, but it 
is likely to be several more years before this can be confirmed.31 Most studies reporting skin 
cancer have focused on maintenance rather than induction therapies and further research is 
needed to guide the safest induction regimes.32  
 
 
 
Other drugs commonly used in transplantation may also influence skin cancer risk. 
Voriconazole is a triazole antifungal used in treatment and prophylaxis of invasive fungal 
infections such as aspergillosis. Retrospective studies have identified it as an independent 
risk factor for cSCC in lung transplant recipients, with multiple and aggressive tumours 
developing after a mean of 35 months.33 Phototoxicity, possibly enhanced by 
immunodeficiency, may underpin the mechanism of action: a multistep photo‐induced 
process with acute phototoxicity in the first year, actinic keratoses in the second/third year 
and cSCC by the third year onwards has been observed.34 Moxifloxacin is a quinolone - a 
class of antibiotics associated with acute phototoxicity - and was recently linked to cSCC in 
lung transplant recipients.35 Even more frequently used in OTRs are statins and non‐
steroidal anti‐inflammatory drugs, classes of drugs have been linked to both increased and 
reduced risk of skin cancer:  their risk status in OTRs remains uncertain.36,37,38,39 
 
Tumour microenvironment  
In addition to systemic immune dysregulation, the local tumour microenvironment plays a 
critical role in cancer.40 There is evidence for a unique immune microenvironment in OTR 
cSCC: whilst higher numbers of circulating regulatory T cells are predictive for new cSCC 
development,41 the density of tumour inflammatory infiltrate is reduced42 and reduced 
CD4+ and cytotoxic CD8+ T cells infiltration, increased regulatory T cells and a blunted Th17 
and Tc22 response are all predicted to lead to a ‘permissive’ tumour microenvironment with 
decreased immune surveillance43-46. Impaired antigen presentation (though reduced 
CD123+ plasmacytoid dendritic cells43 and increased exposure to IL‐2245) may also 
accelerate tumour growth and may contribute to the aggressive nature of some OTR cSCC. 
Most recently, immunological senescence detectable by increasing CD57 expression on 
circulating T cells was linked to increased skin cancer development in OTR and may 
represent a future predictive biomarker for cSCC risk.46  
 
The mesenchymal component of the dermal compartment is also emerging as a potentially 
powerful driver for cSCC. Although not specifically studied in OTR, loss of mesenchymal 
Notch1 signalling in animal models causes stromal alterations which preceded KC formation, 
changes also identified in stroma adjacent to actinic keratoses/field cancerisation in human 
 
 
samples and inducible by UVA.47 Given the enhanced UVA effects in OTRs receiving both 
azathioprine and cyclosporine,5,9,14-22 it is possible that these dermal effects may play a 
particularly important role in OTR field cancerization /  cSCC and  may have implications for 
optimising delivery and efficacy of topical chemopreventative approaches. 
 
Human papillomavirus (HPV) infection 
The most common malignancies in immunosuppressed groups are those due to known or 
suspected oncogenic viruses.2 In the skin, these include Kaposi sarcoma (human herpes 
virus 8), post‐transplant lymphoproliferative disorders (Epstein Barr Virus) and probably 
Merkel cell carcinoma (Merkel cell polyomavirus)48 and a similar role for viruses in OTR cSCC 
has therefore been hypothesised. Human papillomaviruses (HPV) have been a particular 
focus of research efforts for more than three decades, driven by clinical evidence of 
widespread cutaneous HPV infection in OTRs, HPV‐related histological features observed in 
some OTR cSCC and apparent clinical parallels with the rare genodermatosis 
epidermodysplasia verruciformis (EV) in which susceptibility to HPV infection is associated 
with increased risk of cSCC.42,48-51 Current epidemiological and molecular data are 
supportive, but far from conclusive, and this remains an active but controversial area of OTR 
cSCC pathogenesis research.  
 
HPV are small, double-stranded, non-enveloped DNA viruses that infect skin and mucosal 
keratinocytes52. More than 170 types are recognized and classified into alpha, beta, gamma, 
mu, and nu genera.53. Alpha genus mucosal HPV, principally HPV 16 and 18, play a central 
role in anogenital carcinoma, some head and neck SCC (HNSCC) and periungual SCC, all of 
which are more common in immunocompromised populations49. However, HPV of the beta 
(betaPV) rather than alpha genus have been most closely linked with cSCC.48-51 First 
discovered in patients with EV, in whom they are detected in over 90% of cSCC, betaPV 
appear to act as co‐carcinogens with UVR in EV-associated cSCC.51 However, betaPV are also 
present at low level in the skin and hair follicles of more than 80% of healthy people: 
colonization occurs from early childhood onwards and viral load, multiplicity and 
seropositivity are increased by immunosuppression48-51. Such ubiquitous presence of betaPV 
inevitably poses a challenge for interpreting results of the many epidemiological studies 
examining a possible causal association with cSCC. Most recent analyses using state-of-the-
 
 
art techniques for detecting both the presence of HPV DNA and concordant seropositivity 
have shown betaPV infection to be associated with an approximately 2-fold increased risk of 
cSCC in OTR  - of the same order as that conferred by skin phototype - although the 
hierarchy of specific betaPV types likely to be responsible is less consistent between 
studies48-51,54 Further compelling epidemiological data are those from a recent prospective 
cohort study demonstrating seropositivity to betaPV at the time of transplantation is 
predictive for almost 3-fold increased skin cancer risk. 55  
 
Against the background of these complex epidemiological data, mounting evidence from 
biological studies is arguably more convincing and has pointed to possible synergism 
between betaPV and other risk factors, particularly UV48,49,56. The carcinogenic mechanisms 
of high-risk alphaPV in anogenital cancer are well established and, amongst other 
properties, involve inhibition by viral E6 and E7 oncoproteins of the tumour suppressors p53 
and retinoblastoma (pRb), respectively52,53. BetaPVs generally behave differently, probably 
exerting pro-carcinogenic effects chiefly by enhancing accumulation of UV-induced DNA 
damage in the skin51. In normal cells, UV up-regulates cellular defence processes, ultimately 
leading to p53 activation, cell cycle arrest, apoptosis or DNA repair.7,57  Expression of several 
types betaPV E6 and E7 (e.g. 5, 8, 38 and 49) deregulates many of these crucial pathways, 
mainly by directly targeting multiple transcription factors and/or transcriptional regulators, 
rendering infected cells highly susceptible to chromosomal instability and malignant 
transformation by UV.5,48,49,51,58 For example, some betaPV E6 degrade Bak, a Bcl-2 family 
member which mediates UV-induced  apoptosis; some also directly bind p300, the co-
activator of several transcription factors including p53; HPV38 E7 induces  accumulation of a 
p53 antagonist, ΔNp73α, which inhibits expression of several p53-regulated genes. Other 
pro-carcinogenic properties include abrogation of NOTCH tumour suppression, repression of 
TGF beta signalling, enhanced dermal invasion and evasion of host 
immunesurveillance.5,49,51,56 Synergism between betaPV types and UV has been also 
documented in transgenic mouse models using a cytokeratin K14 promoter (K14) to drive E6 
and E7 expression in the basal epidermis: in mice expressing the entire early region of HPV8 
or the E6 gene alone, a single dose of UV rapidly promoted papillomas and cSCC 
formation59,60 and in a K14 HPV38 E6/E7 transgenic model, UV irradiation also induced the 
development of actinic keratoses and cSCC.61  
 
 
Despite these plausible functional data, the role of HPV has been directly challenged by 
studies in which HPV transcriptional activity in cSCC is either low or entirely absent.49,50,56 
Some researchers argue this is incontrovertible evidence that HPV infection is merely a 
marker of global immunosuppression and not pathogenically relevant. An alternative 
interpretation is the ‘hit and run’ hypothesis which proposes that, in direct contrast to 
anogenital SCC where alphaPV persistence is required for tumour maintenance, HPV is 
involved only in tumour initiation of cSCC by predisposing keratinocytes to UV‐induced 
damage and, once this is achieved, the virus is not further required in tumour promotion. 
There is precedent for such a mechanism in bovine papillomavirus-induced oesphageal SCC 
(which, as in OTR cSCC, is associated with exposure to immunosuppressants present in 
ingested bracken) and consistent with this is the observation that betaPV viral load is higher 
in premalignant actinic keratoses compared with cSCC.49-51,56   
 
Continued efforts to definitively clarify the role played by HPV remain a priority, given the 
potential implications for new developing powerful new directions for post-transplant cSCC 
treatment and prevention. HPV vaccination is one such strategy. Although the cornerstone 
of anogenital cancer prevention, existing vaccines provide type-restricted protection against 
alpha rather than betaPV types and so the rationale for their use in cSCC is less convincing. 
However, animal studies have shown that vaccination against betaPV types is a feasible 
approach to cSCC prevention, even in the setting of immunosuppression.62,63 and recent 
experimental data hold promise that effective, next generation vaccine candidates targeting 
cutaneous HPV infection are in sight64. Although the human situation is complicated by 
uncertainties relating to the highest risk viruses, prevention or timely treatment of specific 
betaPV infections by vaccination or even antiviral drugs remains a possible future approach 
for reducing cSCC burden in OTR.  
Genetic and epigenetics alterations 
Skin tumours are amongst the most highly mutated of all human cancers due largely to the 
mutagenicity of both UVB and UVA and cumulative UV-exposure.7,57 The emerging 
landscape of genomic alterations in cSCC underscores this high mutational burden, 
dysregulation of multiple signalling pathways and tumour heterogeneity.57 Amongst studies 
documenting these changes, several have included analysis of OTR cSCC and, although there 
 
 
appear to be some differences to ICP cSCC, none are yet identified that fully explain either 
the altered frequency or biological behaviour of OTR cSCC. Nonetheless, given the current 
pace of methodological advances, such genetic differences may yet emerge and provide 
clinically relevant insights into the pathogenesis of OTR cSCC, identifying new therapeutic 
targets and/or diagnostic and prognostic biomarkers in the process.  
 
At the chromosomal level, studies assessing copy number aberrations in cSCC have shown 
high levels of genetic instability, with similar patterns across both OTR and ICP tumours.57,65 
However, some researchers suggest that this instability is lower in OTRs,66 possibly an 
indication that other factors such HPV may be playing a significant role, as in HNSCC in 
which HPV-positive tumours have fewer genetic alterations than non-virally driven tumours. 
These studies would also need to stratify for additional features including cSCC 
differentiation (which may influence genetic instability7,65) and are likely to be complicated 
by the finding that independent OTR cSCC arising in the same individual appear to show 
evidence of similar allele specific imbalances, suggesting the genetic background of an 
individual may also influence somatic events.67  
 
At the individual gene level, most OTR cSCC harbour typical UV signature mutations7, 
although the existence of drug-associated mutational signatures has been suggested for 
azathioprine and may underscore the importance of its direct carcinogenic effects17. The 
massive mutational burden of cSCC makes it difficult to distinguish cancer ‘drivers’ from vast 
numbers of ‘passenger’ genetic events and critical genes have not been well defined. 
Nonetheless, the overall pattern emerging is of early loss of specific tumour suppressors 
(TP53, NOTCH1/2, CDKN2A) with subsequent involvement of diverse oncogenes, but these 
studies have not shown consistent differences between OTR cSCC and ICP cSCC57.  
 
TP53 is one of the most commonly mutated genes and occur early, already frequent and 
seemingly tolerated in normal skin.68,69 TP53 mutations were more prevalent in normal skin 
adjacent to OTR versus ICP cSCC in one series, although the reasons for this are not clear 
and possibly point to enhanced clonal expansion of UV damaged keratinocytes in OTRs, 
perhaps due to immunosuppressive drugs or other risk factors.70 In contrast, 30% of OTR 
cSCC in another small study were negative for abnormal TP53 immunostaining, which was 
 
 
universally present in ICP tumours, and this might once again support a viral aetiology with 
alternative p53 attenuation through interaction of viral-host proteins.71  
 
Even more frequent is mutation of NOTCH family genes.7 A recent ground-breaking study 
using ultra deep sequencing of normal skin from eyelid biopsies showed an especially high 
prevalence of NOTCH1 loss with biallelic NOTCH1 inactivation found in up to 25% of normal 
keratinocytes.69 This has not yet been similarly evaluated in OTR normal skin, but might 
prove even higher if the findings for p53 are replicated, although betaPV might alternatively 
attenuate NOTCH activity56. These findings raise intriguing questions about the 
gatekeeper(s) limiting progression from UV damaged skin to actinic keratoses and invasive 
cSCC: they may point to immune surveillance rather than specific genetic factors as critical 
and this may help to explain the increased prevalence and more rapid progression of cSCC in 
OTR and other immunosuppressed individuals.  
 
Cancer signalling pathways in cSCC have also been evaluated in transcriptome studies and 
confirm RAS/MAPK pathway upregulation as characteristic of progression from actinic 
keratoses to cSCC in both ICP and OTR cSCC72. Inhibition of PI3K/AKT/mTOR activation has 
already proved important in secondary prevention of OTR cSCC.24,25 Activation of 
transforming growth factor beta-1 (TGFbeta 1) signalling has also reported.72 Recent data 
underscore its importance in driving cSCC development in general73 and increased TGFbeta 
signalling has been observed in studies of OTR cSCC specifically: in the first,  elevated 
phospho(P)-SMAD2 levels, key proteins in TGFbeta signalling, were found in both non-
lesional skin and cSCC in OTR relative to non-transplanted individuals,74 confirmed in a 
second study.75 Risk factors other than UV may modulate these pathways: for example, 
cyclosporine interacts with TGFbeta signalling and the effects of sirolimus on mTOR 
signalling may in part explain its effects in secondary prevention of OTR cSCC9. 
 
Epigenetic changes in cSCC, including DNA methylation, histone acetylation and the activity 
of microRNAs, represent important targets for possible therapeutic intervention although 
published data remain limited.57 OTR cSCC have been included in a few studies only:  p16 
methylation was found to be higher in ICP cSCC and miR-135 expression was similar in both 
OTR and ICP cSCC77, but this is an area where further research should particularly focus 
 
 
given that, compared with genetic mutations, epigenetic alterations are generally more 
tractable therapeutic targets.  
 
Finally, in germs of genetic susceptibility, as discussed by Madeleine et al, germline single 
nucleotide polymorphisms (SNPs) may be associated with increased cSCC risk, although only 
a few studies have been conducted in OTR and as such they cannot yet be used for risk 
prediction.1  
 
Conclusions 
In this review, we have highlighted key data underpinning current understanding of factors 
influencing the pathogenesis of cSCC arising in OTR (Figure 1a). The striking increase in cSCC 
incidence and the accelerated progression from sun exposed skin, to actinic keratoses, cSCC 
and metastasis experienced by OTRs emphasises how critical an intact immune system is to 
both pathogenesis and clinical behaviour of cSCC. Unravelling the relative importance and 
complex interdependencies of UV, immune surveillance, pro- / anti-carcinogenic drugs 
effects and beta-papillomaviruses, genetic alterations and host genetic susceptibilities 
remains a challenging task, yet will undoubtedly be essential for future development and 
optimisation of rational therapeutic and preventative interventions (Figure 1b).  
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Figure 1: Summary of the complex interplay of multiple influences in the development and 
progression of cutaneous squamous cell carcinoma in OTR  
 
